Dupixent CTCL Studies Highlighted Cancer Risks For Years, Lawsuit Alleges

Anne Gibson, a Colorado resident, filed a product liability complaint in U.S. District Court for the District of New Jersey on August 3, 2026, naming Sanofi-Aventis U.S. LLC, Genzyme Corporation, and Regeneron Pharmaceuticals Inc. as defendants. Gibson alleges she was prescribed Dupixent for atopic dermatitis and subsequently developed cutaneous T-cell lymphoma, which she contends was caused by the drug.

The lawsuit claims that manufacturers possessed knowledge from clinical trials for years before the FDA approved Dupixent in 2017 that the medication posed a risk of causing CTCL, a rare form of cancer. According to the complaint, defendants withheld this safety information to preserve the substantial profits generated by the blockbuster drug. Dupixent was initially approved to treat atopic dermatitis but manufacturers have since sought expanded indications for asthma, chronic obstructive pulmonary disease, and other immune-related conditions.

An MDL judge is scheduled to conduct an initial case management conference with counsel in October 2026, indicating that multiple Dupixent-related claims are being consolidated for coordinated litigation.

This is a curated brief from the PlaintiffWire news desk. Read the original report at AboutLawsuits.